A cholesterol amino derivative-sucrose ester type cationic liposome / gene complex and its preparation method
The cationic liposomes formed by the complexation of cholesterol amino derivatives and sucrose ester lipids has solved the toxicity and stability of cationic liposomes in gene therapy, achieved efficient and low toxic gene transfection, and promoted genes The development of treatment.
Patent Information
- Application Number
- CN202210144344.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-17
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-02-17
AI Technical Summary
The existing cationic liposomes have problems such as high toxicity, poor biocompatibility and low transfection efficiency in gene therapy, especially cholesterol instability, which leads to off-target nucleic acids, which limits their clinical application.
A cholesterol amino derivative-sucrose ester type cationic liposome/gene complex was designed, and a new cationic liposome was formed by combining cholesterol amino derivative with sucrose ester lipid TSI14, and prepared by hydrating film method. Binding plasmid DNA to improve transfection efficiency and reduce toxicity.
It significantly improves the efficiency of gene transfection, reduces cytotoxicity, provides a safer and more efficient gene introduction system, and has broad prospects for gene therapy application.
Smart Images

Figure CN114306641B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a cholesterol amino derivative-sucrose ester type cationic liposome / gene complex and a preparation method thereof, belonging to the field of gene therapy. Background Art
[0002] Gene therapy is a biological therapy method that uses gene transfer technology to introduce exogenous normal genes into target cells to correct or compensate for diseases caused by gene defects and abnormalities to achieve the purpose of treatment. With the advent of the era of precision medicine, gene therapy plays an increasingly important role in clinical treatment. Among the gene therapies that have entered clinical research, tumor-related gene therapy accounts for more than half.
[0003] There are two main types of vectors used in gene therapy: viral vectors and non-viral vectors. Currently, gene therapy is still facing many problems and challenges: immune response; too few therapeutic genes; how to develop efficient, low-toxic, targeted gene delivery systems and polygenic diseases. Among them, obtaining an efficient and safe gene delivery system is undoubtedly the key to the success of gene therapy.
[0004] Cationic liposomes have the advantages of low toxicity, high transfection efficiency and wide transfection range. As non-viral gene carriers, they are increasingly valued in the field of gene therapy. At present, the most widely used non-viral gene carriers include naked DNA, cationic polymers, liposomes, etc. Among them, naked DNA is the simplest non-viral vector, which can connect the target gene to the plasmid. This method is easy to prepare but has low transfection efficiency and is easily degraded by nucleases in the body, thus limiting its application. Cationic polymers are usually linear in structure, and their main chain or side chains carry positively charged groups, which have the advantages of high transfection and low toxicity. However, the tight binding of cationic polymers to DNA leads to the inability to effectively release DNA, which becomes a bottleneck restricting its clinical application. The high biocompatibility and good stability of cationic liposomes give it a wide range of application prospects in the field of gene therapy.
[0005] Cationic liposomes are mainly composed of cationic lipids, positively charged lipid derivatives or natural alkaline lipids and neutral lipids. Due to the positive charge carried by cationic liposomes, they can combine with the phosphate groups in gene molecules through electrostatic interaction, wrap up the genes and effectively compress them to form a complex, making it easier for genes to pass through the cell membrane. The development of new and efficient cationic liposomes has become a research hotspot in the field of gene therapy.
[0006] The hydrophilic head region of cationic lipids is usually composed of a head with a positive charge and an ion with a negative charge (balance anion). It is generally believed that the more positively charged the hydrophilic head of the cationic liposome is, the better the transfection efficiency. Therefore, common hydrophilic heads usually contain one or more amino groups, from simple amino groups to quaternary ammonium salts substituted by alkyl or hydroxyalkyl groups and heterocyclic heads, etc. In addition, there are hydrophilic heads with phosphorus or arsenic groups. Cationic liposomes with multiple amino heads have a proton buffering effect and can improve the stability of genes in cells. However, it has been found that the toxicity of cationic lipids stems from their positive charge. The greater the positive charge density, the higher the toxicity. Therefore, this also has a negative impact on the application of this type of cationic lipids. The heads of the currently synthesized cationic compounds are mostly amino or ammonium salts. It is generally believed that the quaternary ammonium salt type cationic head can effectively bind to nucleic acids and has a higher transfection efficiency. In 1991, Gao et al. reported the synthesis of a cationic lipid DC-Chol with cholesterol as the hydrophobic tail, and successfully transfected cells, becoming the earliest cholesterol lipid. Liposomes prepared from cholesterol-based lipids have become the most widely used delivery method in the field of in vitro plasmid delivery research.
[0007] Helper lipid or co-lipid is an important component of cationic liposome formulation. It has become increasingly indispensable in current research. It is generally a neutral lipid molecule, such as DOPE, dioleoylphosphatidylcholine (DOPC) and cholesterol (Chol). These neutral components stabilize the lipid bilayer membrane structure and reduce the toxicity of positive components. At the same time, they can help the transformation of lipid conformation, which plays a very important role in the release of plasmids in cells and is also one of the means to improve the efficiency of cationic liposome cell transfection. Among them, DOPE and DOPC are phospholipid-type neutral lipid molecules with double hydrophobic tail chain structures, which can make liposomes have strong membrane fluidity. The traditional method of forming cationic liposomes is to use cationic lipids as the main component, supplemented by vesicles formed by helper lipids.
[0008] The invention patent with publication number CN105985386A discloses a type of sucrose ester type cationic lipid and its preparation method. It mainly synthesizes and prepares a type of sucrose ester type cationic lipid. The synthesis method is simple and the product yield is high. At the same time, it briefly discusses the method of mixing the lipid with an auxiliary lipid to prepare a liposome for nucleic acid delivery. This invention patent simply discusses the compounding of cholesterol auxiliary lipid and sucrose ester type cationic lipid. Although the transfection effect has been improved, since the complex needs to deliver nucleic acids into cells, its toxicity, biocompatibility and transfection efficiency still limit its application. In addition, during the delivery process, the instability of cholesterol may cause nucleic acid off-target. Summary of the invention
[0009] The present invention designs a method for preparing a cholesterol amino derivative-sucrose ester type cationic liposome / gene complex, which solves the following technical problems: (1) obtaining an efficient and safe gene introduction system through cholesterol amino derivative-sucrose ester type cationic liposome; (2) preparing a cationic liposome / gene complex with higher biocompatibility and transfection efficiency and lower toxicity; (3) the preparation method is simpler and more convenient, and the product has good stability.
[0010] In order to solve the above-mentioned technical problems, the present invention adopts the following solutions:
[0011] A cholesterol amino derivative-sucrose ester type cationic liposome / gene complex, characterized in that the complex is composed of cholesterol amino derivative-sucrose ester type cationic liposome and gene, and the gene is coated on the outside of the cholesterol amino derivative-sucrose ester type cationic liposome.
[0012] Furthermore, the cholesterol amino derivative-sucrose ester type cationic liposome is obtained by compounding cholesterol or cholesterol amine compounds with quaternary ammonium salt type sucrose ester lipid TSI14; the gene combined with the cholesterol amino derivative-sucrose ester type cationic liposome is plasmid DNA.
[0013] Furthermore, the cholesterol amine compound is one or more of cholesterol ethylamine-sucrose ester compound (DE), cholesterol butylamine-sucrose ester compound (DB), and cholesterol hexylamine-sucrose ester compound (DH).
[0014] A method for preparing a cholesterol amino derivative-sucrose ester type cationic liposome / gene complex, characterized by comprising the following steps:
[0015] Step 1: Treatment of cationic lipids;
[0016] Step 2: Preparation of cholesterol amino derivative-sucrose ester type cationic liposomes;
[0017] Step 3: film blowing and drying;
[0018] Step 4: Hydration;
[0019] Step 5: Preparation of gene complex.
[0020] Furthermore, the specific method of step 1 is: accurately weighing the cationic lipid TSI14 and chloroform to fully dissolve the cationic lipid to obtain a cationic lipid solubilizer A; the mass volume ratio of the cationic lipid TSI14 and chloroform is 1:1-5, and when the cationic lipid TSI14 is 1 mg, the volume of the chloroform is 1 ml-5 ml;
[0021] The specific method of step 2 is: adding cholesterol or cholesterol amine compound to the cationic lipid solute A prepared in step 1, and mixing by vortex oscillator; the molar ratio of the cationic lipid solute A to the cholesterol or cholesterol amine compound is 1:1-20:1;
[0022] The specific method of step three is: using N2 to blow the product obtained in step two into a uniform film, and then placing it in a vacuum drying oven for 5h-36h; the thickness of the blown film is 90μm-100μm;
[0023] The specific method of hydration in step 4 is: slowly add ultrapure water to the product obtained in step 3, repeatedly ultrasonically oscillate 5-10 times at 50 Hz until it is clarified, and finally obtain cholesterol amino derivative-sucrose ester type cationic liposomes; the temperature of ultrasonic washing is 25°C-65°C;
[0024] The step five is: uniformly mixing the cholesterol amino derivative-sucrose ester type cationic liposomes obtained from the step four with the gene complex, and then incubating them to obtain the cholesterol amino derivative-sucrose ester type cationic liposomes and gene complexes due to electrostatic adsorption.
[0025] Furthermore, the cholesterol amine compound described in step 2 is one or more of cholesterol ethylamine-sucrose ester compounds (DE), cholesterol butylamine-sucrose ester compounds (DB), and cholesterol hexylamine-sucrose ester compounds (DH); and the oscillation frequency of the vortex oscillator is 20 Hz.
[0026] Furthermore, the amount of ultrapure water added in step 4 is 1 mL-10 ml, and the temperature of the ultrapure water is 25° C.-65° C.
[0027] Furthermore, in step 5, the mass ratio of the cholesterol amino derivative-sucrose ester type cationic liposome to the gene complex is 1:1-20:1.
[0028] Furthermore, the gene described in step five is plasmid DNA.
[0029] Furthermore, the incubation temperature in step five is 15°C-35°C, and the incubation time is 10min-40min.
[0030] About the inherent mechanism advantages of the present invention:
[0031] Cholesterol is a widely used auxiliary lipid molecule. It does not form a membrane structure by itself, but can be embedded in the phospholipid membrane at a molar ratio of 1:1 or even 2:1. It is a rigid lipid compound with strong hydrophobicity and good biocompatibility. The addition of cholesterol can change the phase transition of the liposome membrane, reduce the fluidity of the membrane, and then increase its stability, thereby changing the transfection efficiency of the liposome and reducing the toxicity of the positive component. Quaternary ammonium salt sucrose ester lipids (codenamed TSI14) have good gene delivery performance when cholesterol is used as an auxiliary lipid. Using cholesterol as the hydrophobic tail can maintain the orderly arrangement of liposomes and maintain the rigidity of the lipid bilayer membrane. Cholesterol derivative liposomes show good stability when atomized, making these analogs more conducive to gene delivery.
[0032] In order to further improve its performance, the present invention utilizes a series of cholesterol amine compounds and combines or compound them with sucrose ester lipids to study their gene delivery performance. The cholesterol skeleton has good lipophilicity. After replacing the hydroxyl groups on cholesterol with amine compounds, the hydrophilic groups and the cholesterol hydrophobic skeleton form a "T"-shaped spatial structure, which can promote cationic lipids to pass through the cell membrane and significantly improve the gene transfection efficiency of cationic lipid carriers in vivo. Moreover, cholesterol is a substance synthesized by the human body and exists in large quantities in the human body. After entering the body, cholesterol-based cationic liposomes can be metabolized by the body and will not cause immune response, greatly reducing toxicity.
[0033] Researchers Han et al. synthesized a cationic lipid COPA with cholesterol as the hydrophobic chain. The lipid has good stability and a higher transfection efficiency than Lipo 2000. The results of the HeLa cell toxicity experiment showed that the cell survival rate was above 80%, which was much lower than the toxicity of traditional liposomes.
[0034] The cholesterol amino derivative-sucrose ester type cationic liposome / gene complex and the preparation method thereof of the present invention have the following beneficial effects:
[0035] (1) The present invention uses quaternary ammonium salt-type sucrose esters with strong gene compression ability as the main component, and combines another cationic ester, that is, a cholesterol amino derivative with proton buffering effect, to form a new type of cationic liposome. Compared with the traditional formula, that is, the combination of cationic liposomes and auxiliary esters, the cholesterol amino derivative-sucrose ester type cationic liposome / gene complex of the present invention has significantly improved transfection performance and significantly reduced cytotoxicity, and has broad development prospects in the field of gene therapy.
[0036] (2) The cholesterol amino derivative-sucrose ester type cationic liposome / gene complex provided by the present invention is prepared by a hydration film method, which is simple and convenient, has good stability, low toxicity, and high transfection efficiency, provides a new idea for gene therapy, and has potential application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 : Transmission electron microscopic comparison of cholesterol amino derivative-sucrose ester type cationic liposomes of Examples 1 to 4 of the present invention;
[0038] Figure 2 : Zeta potential detection diagram of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex of Examples 2 to 7 of the present invention;
[0039] Figure 3 : is the electrophoresis retardation diagram of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex of Examples 1 to 6 of the present invention;
[0040] Figure 4 : This is a diagram showing the expression effect of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex in HeLa cells according to Examples 3 to 7 of the present invention;
[0041] Figure 5 : This is a graph showing the green fluorescence intensity of HeLa cells transfected with pGFP-N1 plasmid mediated by cholesterol amino derivative-sucrose ester type cationic liposomes according to Examples 3 to 7 of the present invention;
[0042] Figure 6 : This is a graph showing the effect of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex on the viability of HeLa cells according to Examples 3 to 7 of the present invention;
[0043] Figure 7 : It is the structural formula of sucrose ester type cationic lipid;
[0044] Figure 8 : is the structural formula of cholesterol ethylamine-sucrose ester compound DE added in the present invention; Fig. 9 : is the structural formula of the cholesterol butylamine-sucrose ester compound DB added in the present invention;
[0045] Fig.10 : is the structural formula of cholesterol hexylamine-sucrose ester compound DH added in the present invention. DETAILED DESCRIPTION
[0046] Combine the following Figures 1 to 10 , the present invention is further described:
[0047] Implementation 1
[0048] Weigh 1 mg of cationic lipid TSI14 and add 1 mL of chloroform to fully dissolve the lipid.
[0049] Cholesterol was added at a molar ratio of 1:1 and mixed by vortexing.
[0050] The film was blown by N2 to form a uniform film with a thickness of 100 μm, which was then placed in a vacuum drying oven and dried for 5 h.
[0051] After hydration, 1 mL of ultrapure water at 55° C. was slowly added, and the mixture was repeatedly washed with ultrasonic oscillation at a frequency of 50 Hz at 25° C. for 5 times until it was clarified, thereby obtaining cholesterol-sucrose ester type cationic liposomes.
[0052] Then, the cholesterol amino-sucrose ester cationic liposomes and the gene complex were uniformly mixed at a mass ratio of 1:1 and incubated at 15°C for 20 minutes. Due to electrostatic adsorption, the cholesterol amino derivative-sucrose ester cationic liposomes and gene complex were obtained.
[0053] Implementation 2
[0054] Weigh 1 mg of cationic lipid TSI14 and add 2 mL of chloroform to fully dissolve the lipid.
[0055] Cholesterol ethylamine-sucrose ester compound (DE) was added at a molar ratio of 2:1 and mixed by vortexing.
[0056] The film was blown by N2 to form a uniform film with a thickness of 100 μm, which was then placed in a vacuum drying oven and dried for 10 h.
[0057] Hydrate, slowly add 1 mL of 55°C ultrapure water, and wash repeatedly at 25°C with ultrasonic oscillation at 50 Hz for 6 times until clear, to obtain cholesterol amino derivative-sucrose ester type cationic liposomes.
[0058] Then, the cholesterol amino derivative-sucrose ester type cationic liposomes and the gene complex were uniformly mixed at a mass ratio of 1:1 and incubated at 20°C for 15 minutes. The cholesterol amino derivative-sucrose ester type cationic liposomes and the gene complex were adsorbed due to electrostatic effect.
[0059] Implementation 3
[0060] Weigh 1 mg of cationic lipid TSI14 and add 3 mL of chloroform to fully dissolve the lipid.
[0061] Cholesterol butylamine-sucrose ester compound (DB) was added at a molar ratio of 3:1 and mixed by vortexing.
[0062] The film was blown by N2 to form a uniform film with a thickness of 100 μm, which was then placed in a vacuum drying oven and dried for 12 h.
[0063] After hydration, 1 mL of ultrapure water at 55° C. was slowly added, and the mixture was repeatedly washed by ultrasonic oscillation at 50 Hz at 55° C. for 8 times until it was clear, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0064] Then, the cholesterol amino derivative-sucrose ester type cationic liposomes and the gene complex were uniformly mixed at a mass ratio of 1:1 and incubated at 25°C for 20 minutes. The cholesterol amino derivative-sucrose ester type cationic liposomes and the gene complex were adsorbed due to electrostatic effect.
[0065] Implementation 4
[0066] Weigh 1 mg of cationic lipid TSI14 and add 4 mL of chloroform to fully dissolve the lipid.
[0067] Cholesterol hexylamine-sucrose ester compound (DH) was added at a molar ratio of 4:1 and mixed by vortexing.
[0068] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 14 h.
[0069] After hydration, 1 mL of ultrapure water at 55° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 50 Hz at 55° C. for 7 times until it was clear, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0070] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 1:1 and incubated at 25°C for 30 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0071] Implementation 5
[0072] Weigh 1 mg of cationic lipid TSI14 and add 1 mL of chloroform to fully dissolve the lipid.
[0073] Cholesterol hexylamine-sucrose ester compound (DH) was added at a molar ratio of 6:1 and mixed by vortexing.
[0074] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 16 h.
[0075] After hydration, 2 mL of ultrapure water at 35° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 45° C. with a frequency of 50 Hz for 7 times until clarified to obtain cholesterol amino derivative-sucrose ester type cationic liposomes.
[0076] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 8:1 and incubated at 25°C for 30 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0077] Implementation List 6
[0078] Weigh 1 mg of cationic lipid TSI14 and add 2 mL of chloroform to fully dissolve the lipid.
[0079] Cholesterol ethylamine-sucrose ester compound (DE) was added at a molar ratio of 8:1 and mixed by vortexing.
[0080] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 18 h.
[0081] After hydration, 3 mL of ultrapure water at 45° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 35° C. with a frequency of 50 Hz for 6 times until it was clarified, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0082] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 9:1 and incubated at 25°C for 20 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0083] Implementation List 7
[0084] Weigh 1 mg of cationic lipid TSI14 and add 1 mL of chloroform to fully dissolve the lipid.
[0085] Cholesterol was added at a molar ratio of 10:1 and mixed by vortexing.
[0086] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 12 h.
[0087] After hydration, 4 mL of ultrapure water at 50° C. was slowly added, and the mixture was repeatedly washed by ultrasonic oscillation at a frequency of 50 Hz at 45° C. for 7 times until it was clarified, thereby obtaining cholesterol-sucrose ester type cationic liposomes.
[0088] Then, the cholesterol amino-sucrose ester cationic liposomes and the gene complex were uniformly mixed at a mass ratio of 6:1 and incubated at 20°C for 15 minutes. Due to electrostatic adsorption, the cholesterol amino derivative-sucrose ester cationic liposomes and gene complex were obtained.
[0089] Implementation 8
[0090] Weigh 1 mg of cationic lipid TSI14 and add 3 mL of chloroform to fully dissolve the lipid.
[0091] Cholesterol ethylamine-sucrose ester compound (DE) was added at a molar ratio of 10:1 and mixed by vortexing.
[0092] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 24 h.
[0093] After hydration, 5 mL of ultrapure water at 40° C. was slowly added, and the mixture was repeatedly washed by ultrasonic oscillation at a frequency of 50 Hz at 30° C. for 8 times until it was clarified, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0094] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 10:1 and incubated at 20°C for 25 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0095] Implementation List 9
[0096] Weigh 1 mg of cationic lipid TSI14 and add 4 mL of chloroform to fully dissolve the lipid.
[0097] Cholesterol butylamine-sucrose ester compound (DB) was added at a molar ratio of 12:1 and mixed by vortexing.
[0098] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 30 h.
[0099] After hydration, 6 mL of ultrapure water at 55° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 65° C. with a frequency of 50 Hz for 5 times until it was clarified, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0100] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 12:1 and incubated at 25°C for 30 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0101] Implementation 10
[0102] Weigh 1 mg of cationic lipid TSI14 and add 5 mL of chloroform to fully dissolve the lipid.
[0103] Cholesterol hexylamine-sucrose ester compound (DH) was added at a molar ratio of 16:1 and mixed by vortexing.
[0104] The film was blown by N2 to form a uniform film with a thickness of 95 μm, and then placed in a vacuum drying oven for 12 h.
[0105] After hydration, 7 mL of ultrapure water at 25° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 60° C. with a frequency of 50 Hz for 10 times until it was clarified, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0106] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 20:1 and incubated at 30°C for 20 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0107] Implementation 11
[0108] Weigh 1 mg of cationic lipid TSI14 and add 2 mL of chloroform to fully dissolve the lipid.
[0109] Cholesterol was added at a molar ratio of 20:1 and mixed by vortexing.
[0110] The film was blown by N2 to form a uniform film with a thickness of 100 μm, and then dried in a vacuum drying oven for 36 h.
[0111] After hydration, 9 mL of ultrapure water at 65° C. was slowly added, and the mixture was repeatedly washed by ultrasonic oscillation at a frequency of 50 Hz at 25° C. for 7 times until it was clarified, thereby obtaining cholesterol-sucrose ester type cationic liposomes.
[0112] Then, the cholesterol amino-sucrose ester cationic liposomes and the gene complex were uniformly mixed at a mass ratio of 16:1 and incubated at 15°C for 40 minutes. Due to electrostatic adsorption, the cholesterol amino derivative-sucrose ester cationic liposomes and gene complex were obtained.
[0113] Implementation 12
[0114] Weigh 1 mg of cationic lipid TSI14 and add 1 mL of chloroform to fully dissolve the lipid.
[0115] Cholesterol ethylamine-sucrose ester compound (DE) was added at a molar ratio of 17:1 and mixed by vortexing.
[0116] The film was blown by N2 to form a uniform film with a thickness of 90 μm, and then dried in a vacuum drying oven for 24 h.
[0117] After hydration, 10 mL of ultrapure water at 55° C. was slowly added, and the mixture was repeatedly ultrasonically cleaned at 35° C. with a frequency of 50 Hz for 8 times until it was clarified, thereby obtaining cholesterol amino derivative-sucrose ester type cationic liposomes.
[0118] Then, the cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were uniformly mixed at a mass ratio of 4:1 and incubated at 35°C for 10 minutes. The cholesterol amino derivative-sucrose ester type cationic liposome and the gene complex were adsorbed due to electrostatic effect.
[0119] Explanation of the abbreviations in the accompanying drawings:
[0120] TSI14+C is the reaction product of TSI14 in Example 1 with cholesterol added, where C represents cholesterol;
[0121] TSI14+DE is the reaction product of TSI14 in Example 2 with cholesterol ethylamine-sucrose ester compound, and DE represents cholesterol ethylamine-sucrose ester compound;
[0122] TSI14+DB is the reaction product of TSI14 in Example 3 and cholesterol butylamine-sucrose ester compound, DB represents cholesterol butylamine-sucrose ester compound;
[0123] TSI14+DH is the reaction product of TSI14 in Example 4 and cholesterol hexylamine-sucrose ester compound, and DH represents cholesterol hexylamine-sucrose ester compound.
[0124] Figure 1 The transmission electron microscopy comparison of cholesterol amino derivative-sucrose ester type cationic liposomes of Examples 1 to 4 of the present invention. Among them, the accelerating voltage is 100KV, A: TSI14+C, B: TSI14+DE, C: TSI14+DB, D: TSI14+DH. It can be seen from the figure: the basic morphological characteristics of the gene complex prepared in Examples 1 to 4 of the present invention.
[0125] Figure 2 This is the Zeta potential detection diagram of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex of Example 2-Example 7 of the present invention. It can be seen from the figure that: with the increase of N / P, the zeta potential gradually changes from negative to positive. For liposome TSI14+C, when the ratio is 8 / 1, the liposome is completely complexed with DNA, and the potential formed is almost zero. When the ratio of liposome TSI14+DE, TSI14+DB, and TSI14+DH is 6 / 1, the liposome is completely complexed with DNA, and the potential is positive. It shows that the amino groups of DE, DB, and DH can increase the charge of the liposome. The more positive charges they carry, the stronger their ability to bind to DNA, and the more effectively they can compress DNA.
[0126] Figure 3The electrophoresis retardation diagrams of cholesterol amino derivative-sucrose ester cationic liposome / gene complexes of Examples 1 to 6 of the present invention. Lane 1 is a marker, λDNA / EcoR I+Hind III marker from SABC, lane 2 is naked pDNA (0.5 μg), lanes 3 to 10 are pDNA lipid complexes (0.5 μg), and the ratios gradually increase (N / P, 1:1, 2:1, 3:1, 4:1, 6:1 and 8:1). TSI14+DE, TSI14+DB, TSI14+DH and TSI14+C can all bind well to DNA. When the N / P ratio of liposome TSI14+DE is 4 / 1, DNA begins to retard, and when N / P reaches 6 / 1, DNA can be completely retarded; liposomes TSI14+DB and TSI14+DH are similar to TSI14+DE, both of which begin to retard when the N / P ratio is 4 / 1, and DNA can be completely retarded when N / P reaches 6 / 1; when the N / P ratio of liposome TSI14+C is 6 / 1, DNA begins to retard, and when N / P reaches 8 / 1, DNA can be completely retarded. Therefore, it can be further explained that DE, DB and DH can enhance the charge of cationic liposomes. Combined with the zeta potential results of liposome / DNA complexes, the potential of liposome TSI14+C is almost zero when N / P is 8 / 1, and the potential of liposomes TSI14+DE, TSI14+DB, and TSI14+DH is close to zero when N / P is 6 / 1. The above-mentioned agarose gel electrophoresis results are basically consistent with the zeta potential results of the complex.
[0127] Figure 4 : This is a graph showing the expression effects of cholesterol amino derivative-sucrose ester cationic liposome / gene complex in HeLa cells of Examples 3-7 of the present invention. When N / P is 3 / 1, 4 / 1, 6 / 1, 8 / 1, and 10 / 1, the four liposomes can effectively transfect HeLa cells. When N / P is 8 / 1, the green fluorescence is the most and the fluorescence intensity is the strongest, indicating that the transfection effect of the liposome is best at this ratio. The fluorescence intensity of liposomes TSI14+DE, TSI14+DB, and TSI14+DH are all higher than that of liposomes TSI14+C, proving that the compounded liposomes can enhance the transfection efficiency of cells. And compared with the commercial reagent Lipo2000, when N / P is 8 / 1, the transfection efficiency of TSI14+DE and the two are comparable.
[0128] Figure 5: This is a graph of the green fluorescence intensity of HeLa cells transfected with pGFP-N1 plasmid mediated by cholesterol amino derivative-sucrose ester cationic liposomes in Examples 3 to 7 of the present invention. The fluorescence intensity expressed by the four liposomes was the strongest when N / P was 8 / 1, which were 2.95×10 6, 3.21×10 6, 3.13×10 6, and 3.11×10 6, respectively. At the same N / P, the transfection efficiency of TSI14+DE, TSI14+DB, and TSI14+DH was higher than that of TSI14+C. The transfection efficiency of TSI14+DE at N / P of 8 / 1 was equivalent to that of Lipo2000. The experimental results can further show that the compounded liposomes can enhance the transfection efficiency of cells.
[0129] Figure 6 :It is the effect of cholesterol amino derivative-sucrose ester type cationic liposome / gene complex on HeLa cell survival rate of Example 3-Example 7 of the present invention. As the liposome / DNA ratio increases, the cytotoxicity of the liposome gradually increases. When N / P is 10 / 1, the cell survival rate is the lowest. The cell survival rates of TSI14+C, TSI14+DE, TSI14+DB, and TSI14+DH are 78%, 81%, 80%, and 80%, respectively. The reason may be that the increase in the ratio leads to an increase in particle size and zeta potential. The positive charge on the surface of the cationic ion will produce mutual electrostatic interaction with the cell membrane, and this excessive electrostatic interaction may damage or cause cell aggregation, thereby increasing cytotoxicity. When N / P is 8 / 1, the cell survival rates of TSI14+C, TSI14+DE, TSI14+DB, and TSI14+DH in cells are 84%, 89%, 87%, and 86%, respectively, and the cell survival rates are all above 80%. The cell survival rates of TSI14+DE, TSI14+DB, and TSI14+DH at 8 / 1 are all greater than those of TSI14+C, and are only 1%-4% lower than those of Lipo2000. The experimental results show that the cytotoxicity of the three liposomes TSI14+DE, TSI14+DB, and TSI14+DH after compounding is lower than that of liposome TSI14+C, and the addition of cholesterol amine compounds can improve the problem of high cytotoxicity of quaternary ammonium salt cationic lipids.
[0130] Figure 7 The structural formula of sucrose ester type cationic lipids is given; Figure 8 The structural formula of cholesterol ethylamine-sucrose ester compound DE added in the present invention; Fig. 9 The structural formula of the cholesterol butylamine-sucrose ester compound DB added in the present invention; Fig.10 The structural formula of the cholesterol hexylamine-sucrose ester compound DH added in the present invention is shown.
[0131] (1) The present invention uses quaternary ammonium salt-type sucrose esters with strong gene compression ability as the main component, and combines another cationic ester, that is, a cholesterol amino derivative with proton buffering effect, to form a new type of cationic liposome. Compared with the traditional formula, that is, the combination of cationic liposomes and auxiliary esters, the cholesterol amino derivative-sucrose ester type cationic liposome / gene complex of the present invention has significantly improved transfection performance and significantly reduced cytotoxicity, and has broad development prospects in the field of gene therapy.
[0132] (2) The cholesterol amino derivative-sucrose ester type cationic liposome / gene complex provided by the present invention is prepared by a hydration film method, which is simple and convenient, has good stability, low toxicity, and high transfection efficiency, provides a new idea for gene therapy, and has potential application value.
[0133] The present invention has been exemplarily described above in conjunction with specific embodiments and accompanying drawings. It is obvious that the implementation of the present invention is not limited to the above-mentioned methods. As long as various improvements are made using the method concepts and technical solutions of the present invention, or the concepts and technical solutions of the present invention are directly applied to other occasions without improvement, they are all within the protection scope of the present invention.
Claims
1. A cholesterol amino derivative-sucrose ester type cationic liposome / gene complex, characterized in that: The complex is composed of a cholesterol amino derivative-sucrose ester type cationic liposome and a gene, and the gene is coated on the outside of the cholesterol amino derivative-sucrose ester type cationic liposome; The cholesterol amino derivative-sucrose ester type cationic liposome is obtained by compounding a cholesterol amine compound with a quaternary ammonium salt type sucrose ester lipid TSI14; the gene combined with the cholesterol amino derivative-sucrose ester type cationic liposome is a plasmid DNA; The cholesterol amine compound is one or more of cholesterol butylamine and cholesterol hexylamine; The mass ratio of the cholesterol amino derivative-sucrose ester type cationic liposome to the gene complex is 8:
1.
2. A method for preparing a cholesterol amino derivative-sucrose ester type cationic liposome / gene complex, characterized in that The following steps are involved: Step 1: Treatment of cationic lipids; Step 2: Preparation of cholesterol amino derivative-sucrose ester type cationic liposomes; Step 3: film blowing and drying; Step 4: Hydration; Step 5: Preparation of gene complex; The specific method of step 1 is: accurately weigh the cationic lipid TSI14 and chloroform to fully dissolve the cationic lipid to obtain a cationic lipid solubilizer A; the mass volume ratio of the cationic lipid TSI14 and chloroform is 1:1-5, and when the cationic lipid TSI14 is 1 mg, the volume of the chloroform is 1 ml-5 ml; The specific method of step 2 is: adding a cholesterol amine compound to the cationic lipid solute A prepared in step 1, and mixing by vortex oscillator; the molar ratio of the cationic lipid solute A to the cholesterol amine compound is 1:1-20:1; The specific method of step three is: using N2 to blow the product obtained in step two into a uniform film, and then placing it in a vacuum drying oven for 5h-36h; the thickness of the blown film is 90μm-100μm; The specific method of hydration in step 4 is: slowly add ultrapure water to the product obtained in step 3, repeatedly ultrasonically oscillate 5-10 times at 50 Hz until it is clarified, and finally obtain cholesterol amino derivative-sucrose ester type cationic liposomes; the temperature of ultrasonic washing is 25°C-65°C; The step five is: uniformly mixing the cholesterol amino derivative-sucrose ester type cationic liposomes obtained from the step four with the gene complex, and then incubating the mixture to obtain the cholesterol amino derivative-sucrose ester type cationic liposomes and the gene complex due to electrostatic adsorption; The cholesterol amine compound in step 2 is one or more of cholesterol butylamine and cholesterol hexylamine; the oscillation frequency of the vortex oscillator is 20 Hz; The amount of ultrapure water added in step 4 is 1 mL-10 ml, and the temperature of the ultrapure water is 25° C.-65° C.; The cholesterol amino derivative-sucrose ester type cationic liposome and gene complex have a mass ratio of 8:1; The gene described in step 5 is plasmid DNA; The incubation temperature in step 5 is 15°C-35°C, and the incubation time is 10min-40min.
